{"filing":{"accession_number":"0001104659-26-095512","cik":"0001818844","ticker":"DWTX","company_name":"Dogwood Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"dwtx-20260813x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/dwtx-20260813x8k.htm"},"events":[{"id":27568,"run_id":25136,"accession_number":"0001104659-26-095512","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Dogwood Therapeutics issued a press release on August 13, 2026 announcing financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $3.2 million, G\u0026A expenses of $1.6 million, a $9.2 million IPR\u0026D impairment charge, and a net loss of $11.5 million ($0.34 per share). The filing explicitly states this is Item 2.02 disclosure with the press release incorporated as Exhibit 99.1, which is the standard format for quarterly earnings releases. The disclosure includes both operational highlights (clinical trial progress, FDA approvals, scientific advisory board appointment) and detailed financial statements, making it material to investors' assessment of the company's financial condition and progress.","company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29151,"accession_number":"0001104659-26-095512","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood Therapeutics issued a press release on August 13, 2026 announcing financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $3.2 million, G\u0026A expenses of $1.6 million, a $9.2 million IPR\u0026D impairment charge, and a net loss of $11.5 million ($0.34 per share). The filing explicitly states this is Item 2.02 disclosure with the press release incorporated as Exhibit 99.1, which is the standard format for quarterly earnings releases. The disclosure includes both operational highlights (clinical trial progress, FDA approvals, scientific advisory board appointment) and detailed financial statements, making it material to investors' assessment of the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:51:26.759212+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29151,"accession_number":"0001104659-26-095512","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Dogwood Therapeutics issued a press release on August 13, 2026 announcing financial results for the second quarter ended June 30, 2026, including R\u0026D expenses of $3.2 million, G\u0026A expenses of $1.6 million, a $9.2 million IPR\u0026D impairment charge, and a net loss of $11.5 million ($0.34 per share). The filing explicitly states this is Item 2.02 disclosure with the press release incorporated as Exhibit 99.1, which is the standard format for quarterly earnings releases. The disclosure includes both operational highlights (clinical trial progress, FDA approvals, scientific advisory board appointment) and detailed financial statements, making it material to investors' assessment of the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:51:26.759212+00:00","company_name":"Dogwood Therapeutics, Inc.","ticker":"DWTX","filing_date":"2026-08-13"}]}